Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5696501 | 0.98 | SYK (0.40) | SYKOPRM1OPRL1DRD2UHRF1 | |
| SCHEMBL20909918 | 0.84 | UHRF1 (0.42) | SYKOPRM1OPRL1UHRF1CCR1 | |
| SCHEMBL2220946 | 0.76 | SYK (0.38) | SYKOPRM1UHRF1CCR1CCR5 | |
| SCHEMBL20909888 | 0.76 | UHRF1 (0.41) | OPRM1OPRL1UHRF1CCR1CCR5 | |
| SCHEMBL20909880 | 0.75 | UHRF1 (0.39) | SYKOPRM1OPRL1UHRF1CCR1 | |
| SCHEMBL17128356 | 0.75 | OPRM1 (0.42) | SYKOPRM1DRD2SIGMAR1NOS3 | |
| SCHEMBL5696496 | 0.74 | CYP46A1 (0.42) | SYKOPRM1OPRL1CCR1CCR5 | |
| SCHEMBL171507 | 0.74 | OPRM1 (0.53) | OPRM1OPRL1DRD2CCR1SIGMAR1 | |
| SCHEMBL29602661 | 0.74 | OPRM1 (0.53) | OPRM1OPRL1DRD2CCR1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL20744290 | 0.72 | OPRM1 (0.51) | OPRM1OPRL1DRD2CCR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| CN-101952286-A | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions | ASTRAZENECA AB | 2011-01-19 | — | — | CN | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-1673367-A1 | FUSED LACTAM COMPOUNDS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035523-A1 | FUSED LACTAM COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | SYK 4312/4885OPRM1 210/4885OPRL1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.